)
Nicholas Yoder
Executive Director,
Dyne Therapeutics
Nicholas C. Yoder received his Ph.D. in chemistry from Tufts University and completed a fellowship at the Whitehead Institute at MIT. He started his industrial career at ImmunoGen, where he worked on design and production of antibody-drug conjugates for various cancer indications, innovating with conjugation workflows and contributing to the discovery of pivekimab sunirine and IMGC936, among other programs. He subsequently studied ADCs for stem cell conditioning at Magenta Therapeutics. His current work focuses on receptor-targeted oligonucleotide conjugates for genetic disease at Dyne Therapeutics.